Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors

Table 3 Correlation between atezolizumab activity and outcome and programmed cell death protein ligand 1 immunohistochemestry score

Author/study	Marker antibody	Tumor type	Treatment line	PD-L1 cutoff	N pts	Response (%)	mPFS mo (95%CI)	mOS mo (95%CI)
Atezolizumab							NR	NR
							NR	NR
							NR	NR
							NR	NR
Herbst et al[19] Phase I	Ventana SP142	NSCLC	≥ 2	Score 3	6	83	7.8 (2.7-12.3)	15.5 (9.8-NA)
				Score 2	7	14	3.4 (1.4-6.9)	15.1 (8.4-NA)
				Score 1	13	15	3.0 (2.8-4.1)	15.5 (11.1-NA)
				Score 0	20	20	4.1 (2.7-5.6)	9.7 (6.7-12.0)
Fehrenbacher et al[20] POPLAR Phase II	Ventana SP142	NSCLC	≥ 2	Score 3	24	37.50	4.2 (2.9-7.0)	20.5 (17.5-NA)
				Score 2	50	22.00	4.1 (2.8-5.3)	16.3 (13.3-20.1)
				Score 1	93	18.30	4.1 (2.9-4.3)	15.7 (12.6-18.0)
				Score 0	51	14.60	4.0 (3.1-4.2)	12.6 (9.6-15.2)
Rittmeyer et al[21] OAK Phase III	Ventana	NSCLC	≥ 2	Score 3	72	30.60	7.3 (4.9-12.0)	26.9 (12.0-NA)
	SP142			Score 2	129	22.50	7.3 (5.7-9.7)	23.5 (18.1-NA)
				Score 1	241	17.80
				Score 0	80	7.80	7.6 (4.0-9.7)	23.5 (18.1-NA)
Wakelee et al[22] and Antonia et al[23] BIRCH Phase II	Ventana	NSCLC	1	Score 3	65	34
	SP142			TC2/3 or IC2/3	138	25
				Score 2	73	18

Score 3: PDL1 expression levels TC3 or IC3 (≥ 50% on TC or ≥ 10% on IC); Score 2: TC2 or IC2 (≥ 5%-< 50% on TC or ≥ 5% -< 10% IC); Score 1: TC1 or IC1 (≥ 1% - < 5% on TC or IC); Score 0: TC0 and IC0 (< 1% on TC and IC). IC: Tumor-infiltrating immune cell; TC: Tumor cell; NR: Not reported; pts: Patients; NA: Not available; NSCLC: Non-small cell lung cancer; PD-L1: Programmed cell death protein ligand 1; mPFS: Median progression free survival; mOS: Median overall survival.